In multiple myeloma (MM), increased glucose metabolism of cancer cells can increase the expression of HK-2 and lactate dehydrogenase A (LDHA) to reduce the therapeutic effects of standard care drugs, such as bortezomib and melphalan [133] via inhibiting T cell immunity and promoting cancer stem-like properties. Here, HK2 is linked to cancer.